Recursion Pharmaceuticals (RXRX) Set to Announce Quarterly Earnings on Thursday

Recursion Pharmaceuticals (NASDAQ:RXRX) is scheduled to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.34) EPS. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.01 during midday trading on Tuesday, hitting $6.78. 3,661,469 shares of the stock were exchanged, compared to its average volume of 6,020,572. The business’s 50-day moving average price is $8.29 and its 200 day moving average price is $9.42. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -4.29 and a beta of 0.83. Recursion Pharmaceuticals has a 12 month low of $4.97 and a 12 month high of $15.74.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $4,701,312.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Tina Marriott sold 3,000 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $4,701,312.46. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $9.17, for a total transaction of $104,968.99. Following the completion of the sale, the director now directly owns 7,186,913 shares in the company, valued at approximately $65,903,992.21. The disclosure for this sale can be found here. Insiders sold a total of 202,235 shares of company stock valued at $1,654,400 in the last quarter. 15.75% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RXRX. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.